Inflammation in cancer: A therapeutic target?

Oncology

Volumn 25, Issue 5, 2011, Pages

  Trinchieri, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; FORMYLPEPTIDE RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; MITOCHONDRIAL DNA; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; WNT PROTEIN;

ARTICLE; BRAIN CANCER; CANCER GROWTH; CANCER INFILTRATION; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; COLON POLYP; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DNA DAMAGE; DRUG TARGETING; ESOPHAGUS CANCER; HUMAN; INFLAMMATORY CELL; LUNG CANCER; LYMPHOCYTIC INFILTRATION; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; RECTUM POLYP; RISK REDUCTION; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 79956201390     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Virchov R. Cellular pathology as based upon physiological and pathological histology. Philadelphia: J. B. Lippincott; 1863.
2. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-9.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-45.
4. Pamer EG. Immune responses to commensal and environmental microbes. Nat Immunol. 2007;8:1173-8.
5. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
6. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010;16:1384-90.
7. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, et al. The causes of cancer revisited: mitochondrial malignancy and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med. 2010;31:145-70.
8. KC S, Carcamo JM, Golde DW. Antioxidants prevent oxidative DNA damage and cellular transformation elicited by the over-expression of c-MYC. Mutat Res. 2006;593:64-79.
9. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107:8788-93.
10. Yoon JC, Ng A, Kim BH, et al. Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev. 2010;24:1507-18.
11. Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol. 2005;35:2486-95.
12. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104-7.
13. Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A. 2009;106:20388-93.
14. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med. 2011;208:417-20.
15. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221-5.
16. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222-30.
17. Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208:519-33.